Trial
NCT04393454
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Albert Einstein College of Medicine
Collaborators
—
Condition
Metastatic dMMR Solid Cancer
Intervention
Sirolimus 2mg Tablet
Why stopped
Following discussion with the Cancer Center the PI elected to terminate the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-25